CG Oncology (CGON) Net Income towards Common Stockholders (2023 - 2026)

CG Oncology has reported Net Income towards Common Stockholders for 4 years, with the latest figure at -$60.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 74.42% year-over-year to -$60.1 million; the trailing twelve-month figure through Mar 2026 stood at -$186.5 million (down 76.66% YoY), and the FY2025 full-year result was -$161.0 million, down 82.87% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$60.1 million, down from -$41.3 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was -$12.4 million in Q1 2023, with the low at -$60.1 million in Q1 2026.
• Historically, Net Income towards Common Stockholders has averaged -$29.0 million across 4 years, with a median of -$22.5 million in 2023.
• Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders fell 16.51% — and 2025, when it plunged 119.14%.
• CG Oncology's Net Income towards Common Stockholders stood at -$22.5 million in 2023, then plunged by 41.39% to -$31.8 million in 2024, then decreased by 29.74% to -$41.3 million in 2025, then slumped by 45.68% to -$60.1 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$60.1 million (Q1 2026), -$41.3 million (Q4 2025), and -$43.7 million (Q3 2025), per Business Quant data.